Assembly Biosciences(ASMB)
Focus: Assembly Biosciences is a small-molecule antiviral biotech focused on infectious diseases (primarily hepatitis B and herpes simplex) with early-stage pipeline programs. The company is publicly traded but operates at micro-cap scale with 51-200 employees.
Profile data last refreshed 1h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
1-1 this month
Stable — net -1 jobs in 30d
1 added, 2 removed. Backfill posture.
Should You Work at Assembly Biosciences?
AI assessmentEarly-stage public biotech with focused science but high execution risk and limited near-term financial stability—suitable only for risk-tolerant scientists seeking niche antiviral expertise.
Why Work Here
- Focused antiviral specialty with clear therapeutic focus on chronic hepatitis B, a large unmet market with multiple pipeline candidates in Phase 2
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Early-stage
17 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$29M
Pipeline & Clinical Trials
Quality Improvement
Type 2 Diabetes MellitusVideo-based Task-specific Training
StrokeClinical Trials (1)
Help build intelligence for Assembly Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.